ArriVent BioPharma, Inc. — Form 8-K
Filed October 6, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 78/100
What the filing says
ArriVent's pivotal Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC failed to meet its primary endpoint of progression-free survival (PFS) by blinded independent central review (BICR): firmonertinib 240mg achieved 11.0 months median PFS vs. 9.5 months control (p=0.0654, HR 0.75), while 160mg dose showed 8.4 months (HR 0.91). Secondary endpoints showed clinical benefit including PFS by investigator assessment and 60% confirmed ORR with 240mg dose vs. 33% control. Safety profile was consistent with prior studies with no new signals. The trial enrolled 398 patients globally; ArriVent is evaluating next development steps for firmonertinib.
Why this rating
Failed Phase 3 primary endpoint for lead program worth $763M market cap. Firmonertinib is ArriVent's main asset; clinical failure threatens regulatory approval path despite secondary endpoint signals and prior Breakthrough Therapy Designation.
Tradability signal
SHORT
conviction 40/100 · expected -0.82% over 4 hrs
SHORT (drift): bad news keeps sliding after dissemination — our one persistent measured edge. Similar past filings (38 in this cell) moved +1.36% in the called direction over 4 hrs; shrunk for sample size that's a +0.82% edge. Price is down 59.1% since the filing hit EDGAR — the slide has begun. Exit plan: HARD stop 8% against entry — 1.4× this stock's measured hourly volatility, fixed, not trailing (trails test terribly on these names) — time exit 4 hrs. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it negative)
before filing · preread $28.67 ▲ 135.58% | at our read · unknown $12.17 | +10 min · unknown $12.32 ▲ 1.23% | +30 min pending | +1 hr pending | +4 hrs pending |
The stock had already moved -57.55% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.